News
-
March 23, 2023
22nd Century Group (Nasdaq: XXII) Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Business Update
Read More -
March 23, 2023
22nd Century Group (XXII) Secures $21 Million Debt Financing to Expand Working Capital for Growth Initiatives
Read More -
March 23, 2023
22nd Century Group (Nasdaq: XXII) to Participate in March 2023 Roth Investor Conference
Read More -
February 23, 2023
22nd Century Group (XXII) Accelerates Major Growing Program to Enable Implementation of New Zealand’s Reduced-Nicotine Content Tobacco Law
Read More -
February 23, 2023
Nearly Three Out of Four Colorado Smokers Want to Quit and Now Have a New Option That “Helps You Smoke Less”
Read More -
February 23, 2023
22nd Century Group (Nasdaq: XXII) to Announce Fourth Quarter and Full Year 2022 Results on March 9, 2023
Read More -
January 23, 2023
22nd Century Group (XXII) Acquires RX Pharmatech Ltd, Greatly Strengthening UK and EU Market Position
Read More -
January 23, 2023
22nd Century Group (XXII) Announces Filing of U.S. DMF (Drug Master File) for CBD API; New Global Sales, Marketing and Distribution Agreement with Transo-Pharm for Cannabinoid APIs
Read More -
January 23, 2023
22nd Century Group (XXII) Announces U.S. Distribution Partnerships with Core-Mark and Eby-Brown
Read More -
January 23, 2023
FDA’s Proposed Menthol Ban Advances to Final Rule Status, Greatly Benefits 22nd Century (XXII) by Affirming the Need for VLN(R) Menthol King as a Critical Off-Ramp for Adult Menthol Smokers
Read More -
December 22, 2022
22nd Century Group (XXII) Comments on the Advancement of New Zealand’s National Reduced Nicotine Content Law
Read More -
December 22, 2022
22nd Century Group Provides Update on Grass Valley Facility
Read More